

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/571,991	FIRST NAMED APPLICANT Laurent Francois Andre Hennequin	ATTY. DOCKET NO. 056291-5242
---	---	---------------------------------

RECEIVED

NOV 20 2006

INTERNATIONAL APPLICATION NO. PCT/GB04/03937	
LA. FILING DATE 09/15/2004	PRIORITY DATE 09/19/2003

9629  
 MORGAN LEWIS & BOCKIUS LLP  
 1111 PENNSYLVANIA AVENUE NW  
 WASHINGTON, DC 20004

MORGAN, LEWIS &amp; BOCKIUS LLP

CONFIRMATION NO. 5523

371 FORMALITIES LETTER



\*OC000000021271987\*

Date Mailed: 11/17/2006

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/571,991	PCT/GB04/03937	056291-5242

FORM PCT/DO/EO/922 (371 Formalities Notice)



IFW

**PATENT**  
**Customer No. 22,852**  
**New Attorney Docket No. 09963.0008**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
Robert Hugh Bradbury et al.	)	Examiner: Not Yet Assigned
	)	
Application No.: 10/571,991	)	Confirmation No.: 5523
	)	
Filed: March 15, 2006	)	
	)	
For: QUINAZOLINE DERIVATIVES	)	
	)	
	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The Notification To Comply With Requirements For Patent Applications  
Containing Nucleotide And/Or Amino Acid Sequence Disclosures dated November 17,  
2006, indicates that the nucleotide and/or amino acid sequence disclosure contained in  
the present application does not comply with the requirements for such a disclosure as  
set forth in 37 C.F.R. §§ 1.821-1.825 because Applicants have not provided a  
"Sequence Listing" as a separate part of the disclosure on paper or compact disc and  
has not provided a copy of the "Sequence Listing" in computer readable form. A copy  
of the Notification is submitted herewith.

The present application does not contain any nucleotide and/or amino acid  
sequences which require furnishing of sequence disclosures as set forth in 37 C.F.R.


§§ 1.821-1.825. Accordingly, it is respectfully submitted that this Notification has been issued in error and should be withdrawn.

If there are any fees due in connection with the filing of this response, please charge the fees to Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should also be charged to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: February 14, 2007

By:   
Michele C. Bosch  
Reg. No. 40,524

1265658